

Description

The New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide (157-165, SLLMWITQV) is a peptide corresponding to NY-ESO-1 amino acids 157-165, in which the naturally occurring cysteine (C) at the C-terminus is mutated to Valine (V) to prevent the formation of disulfide bonds. The NY-ESO-1 peptide is widely used to stimulate human NY-ESO-1-specific CD8⁺ T cells.

Background

NY-ESO-1 (also known as Cancer testis antigen 1, or CTAG1B), is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but is re-expressed in multiple myeloma, non-small cell lung carcinoma and, breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors.

Sequence

SLLMWITQV

Species

Human

Supplied As

Liquid, 100 µl

Formulation

1 mM peptide in DMSO

Stability

At least one year at -80°C.

Storage

Upon first thaw, aliquot and store at -80°C. Avoid repeated freeze-thaw cycles.

Application

Stimulation of human NY-ESO-1-specific CD8⁺ T cells

Related Products

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
NY-ESO-1-Specific TCR Lentivirus (Clone c259)	78676	100 µl/2 x 500 µl
NY-ESO-1-Specific TCR Lentivirus (Clone 1G4)	78675	100 µl/2 x 500 µl
MART-1-Specific TCR Lentivirus (Clone DMF4)	78678	100 µl/2 x 500 µl
MART-1-Specific TCR Lentivirus (Clone DMF5)	78679	100 µl/2 x 500 µl
MART-1 Peptide (27-35)	78761	100 µl
MART-1 Peptide (26-35)	78759	100 µl
MART-1 Peptide (26-35, Leu 27)	78760	100 µl